Abstract
The melanocortins are a group of small protein hormones derived by post-translational cleavage of the proopiomelanocortin (POMC) gene product. The known melanocortin hormones include α-melanocyte stimulating hormone (MSH), β-MSH, γ-MSH and adrenocorticotropic hormone (ACTH). Five melanocortin receptors (MC1R through to MC5R) have been identified and most of these show tissue-specific expression patterns, as well as different binding affinities for each of the melanocortin hormones. The central melanocortin system consists of α-MSH, agouti-related protein (AGRP), MC3R and MC4R. AGRP and α-MSH are believed to be the natural antagonist and agonist respectively of MC3R and MC4R. This central melanocortin system is thought to play a fundamental role in the control of feeding and body weight. Knock-out mice models and genetic studies have pointed to the importance of the melanocortins in complex human pathways such as pigmentation, lipolysis, food intake, thermogenesis, sexual behaviour, memory and inflammatory response. Recently the melanocortins and their receptors have been the target for drug-based treatment of human physiological processes. MC3R and MC4R are likely targets for controlling body weight; MC1R may be used in the treatment of inflammation and MC2R for the treatment of glucocortical deficiency. A role for MC5R still remains unclear, but the evidence suggests an exocrine gland function.
Keywords: Melanocortins, MC3R and MC4R, thermogenesis
Current Drug Targets
Title: Melanocortins and their Receptors and Antagonists
Volume: 4 Issue: 7
Author(s): Voisey J., Carroll L. and van Daal A.
Affiliation:
Keywords: Melanocortins, MC3R and MC4R, thermogenesis
Abstract: The melanocortins are a group of small protein hormones derived by post-translational cleavage of the proopiomelanocortin (POMC) gene product. The known melanocortin hormones include α-melanocyte stimulating hormone (MSH), β-MSH, γ-MSH and adrenocorticotropic hormone (ACTH). Five melanocortin receptors (MC1R through to MC5R) have been identified and most of these show tissue-specific expression patterns, as well as different binding affinities for each of the melanocortin hormones. The central melanocortin system consists of α-MSH, agouti-related protein (AGRP), MC3R and MC4R. AGRP and α-MSH are believed to be the natural antagonist and agonist respectively of MC3R and MC4R. This central melanocortin system is thought to play a fundamental role in the control of feeding and body weight. Knock-out mice models and genetic studies have pointed to the importance of the melanocortins in complex human pathways such as pigmentation, lipolysis, food intake, thermogenesis, sexual behaviour, memory and inflammatory response. Recently the melanocortins and their receptors have been the target for drug-based treatment of human physiological processes. MC3R and MC4R are likely targets for controlling body weight; MC1R may be used in the treatment of inflammation and MC2R for the treatment of glucocortical deficiency. A role for MC5R still remains unclear, but the evidence suggests an exocrine gland function.
Export Options
About this article
Cite this article as:
J. Voisey, L. Carroll and A. Daal van, Melanocortins and their Receptors and Antagonists, Current Drug Targets 2003; 4 (7) . https://dx.doi.org/10.2174/1389450033490858
DOI https://dx.doi.org/10.2174/1389450033490858 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mutant Cell Surface Receptors as Targets for Individualized Cancer Diagnosis and Therapy
Current Cancer Drug Targets Polymer Particulates in Drug Delivery
Current Pharmaceutical Design Plasticity of Neuroendocrine-Immune Interactions During Ontogeny: Role of Perinatal Programming in Pathogenesis of Inflammation and Stress- Related Diseases in Adults
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Tracking the Mesenchymal Stem Cell Fate After Transplantation Into the Infarcted Myocardium
Current Stem Cell Research & Therapy Salvage Hypofractionated Radiotherapy in Combination with Bevacizumab in Patients with Recurrent High Grade Glioma: A Mono-institutional Experience
Clinical Cancer Drugs The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry G-Protein Signaling, Lipid Rafts and the Possible Sites of Action for the Antidepressant Effects of n-3 Polyunsaturated Fatty Acids
CNS & Neurological Disorders - Drug Targets Recent Approaches and Success of Liposome-Based Nano Drug Carriers for the Treatment of Brain Tumor
Current Drug Delivery Editorial [Hot Topic: TGF-β As Target in Oncology (Guest Editor: Karl-Hermann Schlingensiepen)]
Current Pharmaceutical Biotechnology CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Synthetic Hammerhead Ribozymes as Therapeutic Tools to Control Disease Genes
Current Gene Therapy Isolation, Structural Determination, and Evaluation of the Biological Activity of 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol [20(S)-25-OCH3-PPD], a Novel Natural Product from Panax notoginseng
Medicinal Chemistry Amino Acid Degrading Enzymes and their Application in Cancer Therapy
Current Medicinal Chemistry E2F1-Mediated Apoptosis as a Target of Cancer Therapy
Current Molecular Pharmacology Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design The Role of ING Tumor Suppressors in UV Stress Response and Melanoma Progression
Current Drug Targets Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
Current Medicinal Chemistry Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects
Current Drug Metabolism